Called enpatoran, the agent targets the Toll-like receptor (TLR) species 7 and 8. Some 50%-60% of patients with systemic ...

Patients with prior treatment for diabetic macular edema (DME) may require more frequent dosing of aflibercept (Eylea), ...

COURAGE was designed to investigate the quality of weight loss in patients with obesity (BMI ≥30 kg/m 2). Treatment is divided into two 26-week periods comprised of a weight-loss phase and a ...

As you recall, the photon trial is a phase 3 trial comparing EYLEA HD to EYLEA 2 milligrams. And so EYLEA 2 mg was dose on label, which is 5 monthly loading doses followed by every 8-week dosing.

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically ...

In the COMET-2 and COMET-3 studies, more than 930 patients with a history of dry eye were randomized to receive either Tryptyr or a vehicle (placebo) treatment. The findings revealed that Tryptyr ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leading biopharmaceutical company with a market capitalization of $62.17 billion, finds itself at a critical juncture as it navigates challenges to its ...

The company’s product portfolio is anchored by Eylea, used in treating various eye diseases, and Dupixent, which has shown significant growth potential across multiple indications. In the first ...

The Seoul Central District Court ruled against Regeneron, which had sought to block Samsung Bioepis from producing and selling a biosimilar referencing the US firm’s Eylea, a blockbuster medicine used ...

Investing,com -- Bayer (OTC: BAYRY) shares rose over 2% on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended a label extension for Eylea 8 ...

Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the label expansion of an 8 mg dose of Eylea, developed in partnership with ...